SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.50
−2.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.0B | 2.2B | 1.9B | 1.2B | 933.0M |
| Cost of Revenue | 818.2M | 881.5M | 319.1M | 150.3M | 140.0M |
| Gross Profit | 1.2B | 1.3B | 1.6B | 1.1B | 793.0M |
| Operating Expenses | |||||
| R&D Expense | 789.4M | 1.5B | 804.5M | 877.4M | 877.1M |
| SG&A Expense | 436.7M | 478.9M | 557.9M | 481.9M | 451.4M |
| General & Admin Expense | 329.1M | 478.9M | 557.9M | 481.9M | 451.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 73.2M | (26.5M) | 2.4M | 1.6M | 714.0K |
| Total Operating Expenses | 1.3B | 2.0B | 1.4B | 1.4B | 1.3B |
| Cost and Expenses | 2.1B | 2.9B | 1.7B | 1.5B | 1.5B |
| Operating Income (EBIT) | (143.2M) | (657.8M) | 218.1M | (267.8M) | (536.2M) |
| Non-Operating | |||||
| Interest Income | 30.0M | 19.6M | 71.8M | 86.0M | 27.7M |
| Interest Expense | 58.4M | 9.7M | 18.4M | 22.0M | 53.2M |
| Net Interest Income | (28.4M) | 9.8M | 53.4M | 64.0M | (25.5M) |
| Other Non-Op Income/Expense | 12.3M | (44.5M) | 42.7M | (252.3M) | (153.8M) |
| Non-Operating Income (excl Interest) | (84.0M) | 34.7M | (61.1M) | 230.3M | 100.5M |
| EBT (Pre-Tax Income) | (130.9M) | (702.2M) | 260.8M | (520.1M) | (690.0M) |
| Income Tax Expense | 5.8M | 11.2M | 25.5M | 15.9M | 13.5M |
| Bottom Line | |||||
| Net Income | (136.7M) | (713.4M) | 235.2M | (536.0M) | (703.5M) |
| Earnings from Cont. Ops | (136.7M) | (713.4M) | 235.2M | (536.0M) | (703.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (136.7M) | (713.4M) | 235.2M | (536.0M) | (703.5M) |
| Per Share | |||||
| Basic EPS | ($1.44) | ($7.13) | $2.47 | ($5.80) | ($8.03) |
| Diluted EPS | ($2.90) | ($7.13) | $2.34 | ($5.80) | ($8.03) |
| Revenue Per Share | $18.73 | $20.98 | $20.01 | $13.46 | $10.66 |
| Shares | |||||
| Basic Shares Outstanding | 105.4M | 104.8M | 95.1M | 92.4M | 87.6M |
| Diluted Shares Outstanding | 105.4M | 104.8M | 107.9M | 92.4M | 87.6M |
| Profitability Metrics | |||||
| EBITDA | (14.6M) | (648.0M) | 316.9M | (453.7M) | (594.9M) |
| D&A | 44.7M | 44.5M | 37.7M | 44.4M | 41.9M |
| EBIT | (59.3M) | (692.5M) | 279.2M | (498.1M) | (636.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026